Generation and characterization of P gene-deficient rabies virus

Virology

Volumn 318, Issue 1, 2004, Pages 295-305

  Shoji, Youko ^a,b   Inoue, Satoshi ^a   Nakamichi, Kazuo ^a   Kurane, Ichiro ^a   Sakai, Takeo ^b   Morimoto, Kinjiro ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b NIHON UNIVERSITY   (Japan)

Author keywords

P gene deficient; Rabies virus; Reverse genetics

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; RABIES VACCINE; VIRUS ENZYME; VIRUS PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; EXPERIMENTAL INFECTION; FEMALE; GENE AMPLIFICATION; GENE FUNCTION; GENE LOSS; GENETIC TRANSCRIPTION; GROWTH RATE; HOST PATHOGEN INTERACTION; IMMUNE RESPONSE; INOCULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGENY; PROTEIN DEFICIENCY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RABIES; RABIES VIRUS; STRAIN DIFFERENCE; SUCKLING; VIRION; VIROGENESIS; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS GENOME; VIRUS IMMUNITY; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

RABIES VIRUS;

EID: 1242319455     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.virol.2003.10.001     Document Type: Article

References (42)

1. Barth R., Diderrich G., Weinmann E. NIH test, a problematic method for testing potency of inactivated rabies vaccine. Vaccine. 6:1988;369-377.
2. Benerjee A.K., Barik S. Gene expression of vesicular stomatitis virus genome RNA. Virology. 188:1992;417-428.
3. Bukreyev A., Skiadopoulos M.H., McAuliffe J., Murphy B.R., Collins P.L., Schmidt A.C. More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved? Proc. Natl. Acad. Sci. U.S.A. 99:2002;16987-16991.
4. Chenik M., Schnell M., Conzelmann K.K., Blondel D. Mapping the interacting domains between the rabies virus polymerase and phosphoprotein. J. Virol. 72:1998;1925-1930.
5. Conzelmann K.K. Nonsegmented negative-strand RNA viruses: genetics and manipulation of viral genomes. Annu. Rev. Genet. 32:1998;123-162.
6. Cox J.H., Dietzschold B., Schneider L.G. Rabies virus glycoprotein: II. Biological and serological characterization. Infect. Immun. 16:1977;754-759.
7. Dietzshold B., Rupprecht C.E., Fu Z.F., Koprowski H. Rhabdoviruses. 3rd ed. Fields B.N., Knipe A.M., Howley P.M. Field Virology. vol. 1:1996;1137-1159 Lippincott-Raven Publishers, Philadelphia, PA.
8. Faber M., Pulmanausahakul R., Hodawadekar S.S., Spitsin S., McGettigan J.P., Schnell M.J., Dietzshold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J. Virol. 76:2002;3374-3381.
9. Flanagan E.B., Ball L.A., Wertz G.W. Moving the glycoprotein gene of vesicular stomatitis virus to promoter-proximal positions accelerates and enhances the protective immune response. J. Virol. 74:2000;7895-7902.
10. Flanagan E.B., Zamparo J.M., Ball L.A., Rodriguez L.L., Wertz G.W. Rearrangement of the genes of vesicular stomatitis virus eliminates clinical disease in the natural host: new strategy for vaccine development. J. Virol. 75:2001;6107-6114.
11. Fu Z.F., Zheng Y., Wunner W.H., Koprwoski H., Dietzshold B. Both the N- and the C-terminal domains of the nominal phosphoprotein of rabies virus are involved in binding to the nucleoprotein. Virology. 200:1994;590-597.
12. Haglund K., Leiner I., Kerksiek K., Buonocore L., Pamer E., Rose J.K. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J. Virol. 76:2002;7506-7517.
13. Hooper D.C., Morimoto K., Bette M., Weihe E., Koprowski H., Dietzshold B. Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J. Virol. 72:1998;3711-3719.
14. Inoue K., Shoji Y., Kurane I., Iijima T., Sakai T., Morimoto K. An improved method for recovering rabies virus from cloned cDNA. J. Virol. Methods. 107:2003;229-236.
15. Inoue S., Sato Y., Hasegawa H., Noguchi A., Yamada A., Kurata T., Iwasaki T. Cross-reactive antigenicity of nucleoproteins of lyssaviruses recognized by a monospecific anti-rabies virus nucleoprotein antiserum on paraffin sections of formalin-fixed tissues. Pathol. Int. 53:2003;525-533.
16. Jacob Y., Badrane H., Ceccaldi P.E., Tordo N. Cytoplasmic dynein LC8 interacts with lyssavirus phosphoprotein. J. Virol. 74:2000;10217-10222.
17. Jacob Y., Real E., Tordo N. Functional interaction map of lyssavirus phosphoprotein: identification of the minimal transcription domains. J. Virol. 75:2001;9613-9622.
18. Li H.O., Zhu Y.F., Asakawa M., Kuma H., Hirata T., Ueda Y., Lee Y.S., Fukumura M., Iida A., Kato A., Nagai Y., Hasegawa M. A cytoplasmic RNA vector derived from nontransmissible Sendai virus with efficient gene transfer and expression. J. Virol. 74:2000;6564-6569.
19. McGettigan J.P., Pomerantz R.J., Siler C.A., McKenna P.M., Foley H.D., Dietzshold B., Schnell M.J. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J. Virol. 77:2003;237-244.
20. Mebatsion T. Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein. J. Virol. 75:2001;11496-11502.
21. Mebatsion T., Konig M., Conzelmann K.K. Budding of rabies virus particles in the absence of the spike glycoprotein. Cell. 84:1996;941-951.
22. Mebatsion T., Weiland F., Conzelmann K.K. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J. Virol. 73:1999;242-250.
23. Morimoto K., Foley H.D., McGettigan J.P., Schnell M.J., Dietzshold B. Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J. NeuroVirol. 6:2000;373-381.
24. Morimoto K., McGettigan J.P., Foley H.D., Hooper D.C., Dietzshold B., Schnell M.J. Genetic engineering of live rabies vaccines. Vaccine. 19:2001;3543-3551.
25. Neumann G., Whitt M.A., Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA-what have we learned? J. Gen. Virol. 83:2002;2635-2662.
26. Pasquini S., Xiang Z., Wang Y., He Z., Deng H., Blaszczyk-Thurin M., Ertl H.C. Cytokines and costimulatory molecules as genetic adjuvants. Immunol. Cell Biol. 75:1997;397-401.
27. Patton J.T., Davis N.L., Wertz G.W. N protein alone satisfies the requirement for protein synthesis during RNA replication of vesicular stomatitis virus. J. Virol. 49:1984;303-309.
28. Pulmanausahakul R., Faber M., Morimoto K., Spitsin S., Weihe E., Hooper D.C., Schnell M.J., Dietzshold B. Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity. J. Virol. 75:2001;10800-10807.
29. Raux H., Flamand A., Blondel D. Interaction of the rabies virus P protein with the LC8 dynein light chain. J. Virol. 74:2000;10212-10216.
30. Reuter J.D., Vivas-Gonzalez B.E., Gomez D., Wilson J.H., Brandsma J.L., Greenstone H.L., Rose J.K., Roberts A. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J. Virol. 76:2002;8900-8909.
31. Roberts A., Buonocore L., Price R., Forman J., Rose J.K. Attenuated vesicular stomatitis viruses as vaccine vectors. J. Virol. 73:1999;3723-3732.
32. Schnell M.J., Conzelmann K.K. Polymerase activity of in vitro mutated rabies virus L protein. Virology. 214:1995;522-530.
33. Schnell M.J., Mebatsion T., Conzelmann K.K. Infectious rabies viruses from cloned cDNA. EMBO J. 13:1994;4195-4203.
34. Seder R.A., Hill A.V. Vaccines against intracellular infections requiring cellular immunity. Nature. 406:2000;793-798.
35. Takamatsu F., Asakawa N., Morimoto K., Takeuti K., Eriguchi Y., Toriumi H., Kawai A. Studies on the rabies virus RNA polymerase: 2. Possible relationships between the two forms of the non-catalytic subunit (P protein). Microbiol. Immunol. 42:1998;761-771.
36. Wagner R.R., Rose J.K. Rhabdoviridae: the viruses and their replication. 3rd ed. Fields B.N., Knipe A.M., Howley P.M. Field Virology. vol. 1:1996;1121-1135 Lippincott-Raven Publishers, Philadelphia, PA.
37. Watanabe T., Watanabe S., Ito H., Kida H., Kawaoka Y. Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. J. Virol. 75:2001;5656-5662.
38. Watanabe T., Watanabe S., Kida H., Kawaoka Y. Influenza A virus with defective M2 ion channel activity as a live vaccine. Virology. 299:2002;266-270.
39. Watanabe T., Waranabe S., Neumann G., Kida H., Kawaoka Y. Immunogenicity and protective efficacy of replication-incompetent influenza virus-like particles. J. Virol. 76:2002;767-773.
40. Wiktor T.J., Macfarlan R.I., Foggin C.M., Koprowski H. Antigenic analysis of rabies and Mokola virus from Zimbabwe using monoclonal antibodies. Dev. Biol. Stand. 57:1984;199-211.
41. Wilbur L.A., Aubert M.F.A. The NIH test for potency. Meslin F.-X., Kaplan M.M., Koprowski H. Laboratory Techniques in Rabies. 1996;360-368 World Health Organization, Geneva, Switzerland.
42. Xiang Z., Ertl H.C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity. 2:1995;129-135.